Mirati Therapeutics news
ΓMirati Therapeutics
09.10.23
Mirati Therapeutics
Bristol Myers is buying Mirati Therapeutics for $5.8 billion, or $58 per share. Deal is expected to close in the first half of 2024.
Bristol Myers is buying Mirati Therapeutics for $5.8 billion, or $58 per share. Deal is expected to close in the first half of 2024.
Source: 
news.bms.com
news.bms.com
0
0
05.05.22
Mirati Therapeutics
Mirati Therapeutics' GAAP loss for 3 months of 2022 was $188.386 million, up 38.8% from $135.68 million in the previous year. Revenues were $709 thousand. The company did not earn revenues a year earlier.
Mirati Therapeutics' GAAP loss for 3 months of 2022 was $188.386 million, up 38.8% from $135.68 million in the previous year. Revenues were $709 thousand. The company did not earn revenues a year earlier.
Source: 
ir.mirati.com
ir.mirati.com
0
0
01.03.22
Mirati Therapeutics
Mirati Therapeutics' GAAP loss for 2021 was $581.784 million, up 62.5% from $357.937 million in the previous year. Revenue increased 5.4 times to $72.092 million from $13.398 million a year earlier.
Mirati Therapeutics' GAAP loss for 2021 was $581.784 million, up 62.5% from $357.937 million in the previous year. Revenue increased 5.4 times to $72.092 million from $13.398 million a year earlier.
Source: ir.mirati.com
ir.mirati.com
0
0
09.11.21
Mirati Therapeutics
Mirati Therapeutics' GAAP loss for 9M 2021 was $382.164 million, up 48.8% from $256.85 million in the previous year. Revenue increased 6.1 times to $71.793 million from $11.69 million a year earlier.
Mirati Therapeutics' GAAP loss for 9M 2021 was $382.164 million, up 48.8% from $256.85 million in the previous year. Revenue increased 6.1 times to $71.793 million from $11.69 million a year earlier.
Source: ir.mirati.com
ir.mirati.com
0
0
06.08.21
Mirati Therapeutics
Mirati Therapeutics' GAAP loss for six months of 2021 was $302.11 million, up 78% from $166.514 million in the prior year. 2021 was $302.11 million, up 78.2% from $169.514 million in the previous year. The company did not generate revenue. A year earlier the figure was $267,000.
Mirati Therapeutics' GAAP loss for six months of 2021 was $302.11 million, up 78% from $166.514 million in the prior year. 2021 was $302.11 million, up 78.2% from $169.514 million in the previous year. The company did not generate revenue. A year earlier the figure was $267,000.
Source: ir.mirati.com
ir.mirati.com
0
0
25.06.21
Mirati Therapeutics
Mirati Therapeutics ΠΏΠΎΠ»ΡΡΠΈΠ»Π° ΡΡΠ°ΡΡΡ Β«ΠΏΡΠΎΡΡΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈΒ» ΠΎΡ FDA Π΄Π»Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Β«ΠΠ΄Π°Π³ΡΠ°Π·ΠΈΠ±Β». ΠΠ½ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ Π΄Π»Ρ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π»ΡΠ΄Π΅ΠΉ Ρ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΈΡ , Ρ ΠΊΠΎΡΠΎΡΡΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΌΡΡΠ°ΡΠΈΡ KRASG12C. Π‘ΡΠ°ΡΡΡ Β«ΠΡΠΎΡΡΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈΒ» ΡΡΠΊΠΎΡΠΈΡ ΠΏΡΠΎΡΠ΅ΡΡ ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.
Mirati Therapeutics ΠΏΠΎΠ»ΡΡΠΈΠ»Π° ΡΡΠ°ΡΡΡ Β«ΠΏΡΠΎΡΡΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈΒ» ΠΎΡ FDA Π΄Π»Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Β«ΠΠ΄Π°Π³ΡΠ°Π·ΠΈΠ±Β». ΠΠ½ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ Π΄Π»Ρ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π»ΡΠ΄Π΅ΠΉ Ρ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΈΡ , Ρ ΠΊΠΎΡΠΎΡΡΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΌΡΡΠ°ΡΠΈΡ KRASG12C. Π‘ΡΠ°ΡΡΡ Β«ΠΡΠΎΡΡΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈΒ» ΡΡΠΊΠΎΡΠΈΡ ΠΏΡΠΎΡΠ΅ΡΡ ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.
Source: ir.mirati.com
ir.mirati.com
0
0
07.05.21
Mirati Therapeutics
Mirati Therapeutics' GAAP loss for 3 months of 2021 was $135.68 million, up 56.6% from $86.655 million in the prior year.
Mirati Therapeutics' GAAP loss for 3 months of 2021 was $135.68 million, up 56.6% from $86.655 million in the prior year.
Source: ir.mirati.com
ir.mirati.com
0
0
26.02.21
Mirati Therapeutics
Mirati Therapeutics' GAAP loss for 2020 was $357.937 million, up 67.8% from $213.256 million in the previous year. Revenue quadrupled to $13.398 million from $3.335 million a year earlier.
Mirati Therapeutics' GAAP loss for 2020 was $357.937 million, up 67.8% from $213.256 million in the previous year. Revenue quadrupled to $13.398 million from $3.335 million a year earlier.
Source: ir.mirati.com
ir.mirati.com
0
0
02.11.20
Mirati Therapeutics
Mirati Therapeutics has completed the public offering of 4,985,706 shares at $202 per paper. Under the SPO, the company sold 4,585,706 shares and 400,000 shares were sold by the company's shareholder. The underwriters sold 625,309 shares of the company itself and 25,000 shares of the company's shareholder as part of a call option exercise. As a result of the...
Mirati Therapeutics has completed the public offering of 4,985,706 shares at $202 per paper. Under the SPO, the company sold 4,585,706 shares and 400,000 shares were sold by the company's shareholder. The underwriters sold 625,309 shares of the company itself and 25,000 shares of the company's shareholder as part of a call option exercise. As a result of the...
Source: ir.mirati.com
ir.mirati.com
0
0
English (US) 